Table 2.
Adverse event, n (%) | Inotuzumab ozogamicin treatment | ||
---|---|---|---|
1.3 mg/m2 (n = 3) | 1.8 mg/m2 (n = 10) | Total (n = 13) | |
(a) all grades in ≥4 patients | |||
Thrombocytopenia | 3 (100) | 10 (100) | 13 (100) |
Leukopenia | 3 (100) | 9 (90) | 12 (92) |
Lymphopenia | 3 (100) | 8 (80) | 11 (85) |
Neutropenia | 3 (100) | 8 (80) | 11 (85) |
Aspartate aminotransferase increased | 3 (100) | 8 (80) | 11 (85) |
Anorexia | 3 (100) | 8 (80) | 11 (85) |
Nausea | 3 (100) | 7 (70) | 10 (77) |
Blood fibrinogen increased | 2 (67) | 7 (70) | 9 (69) |
Alanine aminotransferase increased | 1 (33) | 6 (60) | 7 (54) |
Blood alkaline phosphatase increased | 1 (33) | 6 (60) | 7 (54) |
Hemoglobin decreased | 1 (33) | 6 (60) | 7 (54) |
Malaise | 3 (100) | 3 (30) | 6 (46) |
Blood bilirubin increased | 2 (67) | 4 (40) | 6 (46) |
Headache | 2 (67) | 4 (40) | 6 (46) |
Constipation | 1 (33) | 4 (40) | 5 (39) |
Influenza | 1 (33) | 4 (40) | 5 (39) |
Blood lactate dehydrogenase increased | 2 (67) | 3 (30) | 5 (39) |
Fibrin D dimer increased | 0 | 5 (50) | 5 (39) |
Hyperglycemia | 1 (33) | 4 (40) | 5 (39) |
Stomach discomfort | 1 (33) | 3 (30) | 4 (31) |
Fatigue | 0 | 4 (40) | 4 (31) |
Hypercholesterolemia | 1 (33) | 3 (30) | 4 (31) |
Hypokalemia | 2 (67) | 2 (20) | 4 (31) |
Somnolence | 2 (67) | 2 (20) | 4 (31) |
Epistaxis | 0 | 4 (40) | 4 (31) |
Rash | 1 (33) | 3 (30) | 4 (31) |
(b) grades ≥3 | |||
Thrombocytopenia | 2 (67) | 5 (50) | 7 (54) |
Lymphopenia | 0 | 4 (40) | 4 (31) |
Neutropenia | 1 (33) | 3 (30) | 4 (31) |
Leukopenia | 0 | 2 (20) | 2 (15) |
Blood bilirubin increased | 1 (33) | 0 | 1 (8) |
Hypokalemia | 1 (33) | 0 | 1 (8) |